巨细胞动脉炎眼部受累患者的特征与结局:一项病例对照研究
该回顾性单中心队列纳入409例连续巨细胞动脉炎(GCA)患者,比较104例诊断时有视觉症状者与104例年龄性别匹配无眼部受累对照。视觉症状组发热、风湿性多肌痛更少且急性期反应物更低;前部缺血性视神经病变(AION)占45%,即使75%接受静脉甲泼尼龙冲击,65%的AION和/或视网膜中央动脉阻塞患者仍遗留明确盲或重要视觉损害。
要点
- GCA诊断时约四分之一患者存在眼部受累,AION是最常见眼部诊断。
- 视觉症状组发热、风湿性多肌痛及急性期反应物水平低于无眼部受累者。
- 静脉甲泼尼龙冲击未降低AION和/或CRAO患者遗留盲或重要视觉损害的风险。
核心结论
- 眼部受累见于约四分之一GCA患者,AION仍与最差视觉预后相关,静脉甲泼尼龙冲击在本研究中未降低盲风险。
研究设计与样本
- 回顾性单中心队列纳入409例连续GCA患者,其中104例诊断时有视觉症状,与104例年龄性别匹配无眼部受累对照比较。
- 每项视觉症状由眼科医生集中重新评估并对应眼科诊断。
主要发现
- 与对照相比,视觉症状组发热更少(p=0.0006)、风湿性多肌痛更少(p=0.02)、急性期反应物更低(p=0.004)。
- 诊断前视觉症状包括视物模糊(60%)、一过性黑矇(18%)、复视(13%)和永久性视力丧失(9%)。
- AION见于47例(45%),CRAO见于15例(15%),2例同时存在两种受累。
- 糖皮质激素启动延迟在有无视觉症状组间无差异(p=0.06)。
- 60例初始AION和/或CRAO患者中39例(65%)遗留明确盲或重要视觉损害,其中45例(75%)接受过静脉甲泼尼龙冲击。
临床怎么用
- GCA诊断时需警惕眼部受累,尤其对无发热、无风湿性多肌痛且急性期反应物不高的患者。
- 对AION和/或CRAO患者应告知即使接受静脉甲泼尼龙冲击仍可能遗留严重视觉损害。
局限性
- 本研究为回顾性单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the characteristics and outcome of patients with giant-cell arteritis (GCA)-related ophthalmologic involvement at diagnosis. METHODS: In a retrospective single-center cohort of 409 consecutive patients with GCA, we retrieved 104 patients with visual symptoms at GCA diagnosis and we compared them to 104 age- and sex-matched controls without ophthalmologic involvement. Each visual symptom was associated to an ophthalmologic diagnosis that was centrally re-assessed by an ophthalmologist. RESULTS: Compared to controls, patients with visual symptoms showed less fever (p = 0.0006), less polymyalgia rheumatica (p = 0.02) and lower acute phase reactants (p = 0.004). Blurred vision (in 60% of patients), amaurosis fugax (in 18%), diplopia (in 13%) and permanent visual loss (in 9%) were the four visual symptoms described by patients before GCA diagnosis. Anterior ischemic optic neuropathy (AION) was found in 47 (45%) patients, followed by central retinal artery occlusion (CRAO) in 15 (15%). Two patients had both involvements. The delay of glucocorticoids initiation was not different between patients with and without visual symptoms (p = 0.06). Among the 60 patients with initial AION and/or CRAO, 39 (65%) kept definite blindness or important visual damage, although 45 (75%) had received intravenous (IV) pulses of methylprednisolone. A new ischemic event (AION in all cases) occurred in 4% of patients with visual symptoms despite the initiation of treatment. CONCLUSION: Ophthalmologic involvement was observed in one-quarter of our GCA patients. AION is still associated with the worst visual prognosis, and IV methylprednisolone pulses did not reduce the risk of blindness in our study.
引用
- Dumont A, Lecannuet A, Boutemy J, et al. Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study. Semin Arthritis Rheum. 2020. PMID: 32192630. doi:10.1016/j.semarthrit.2019.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。